- Trials with a EudraCT protocol (62)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (190)
62 result(s) found for: BAT.
Displaying page 1 of 4.
EudraCT Number: 2016-002373-35 | Sponsor Protocol Number: T153/2016 | Start Date*: 2016-07-04 |
Sponsor Name: | ||
Full Title: The Effects of Dietary Peptides on Human Brown Adipose Tissue | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004059-34 | Sponsor Protocol Number: C7Q040 | Start Date*: 2021-02-25 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Stimulation of the beta-2 adrenergic receptor for activating human brown adipose tissue | |||||||||||||
Medical condition: Obesity, overweight, lipid- and glucose metabolism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004432-38 | Sponsor Protocol Number: CINC424D2301 | Start Date*: 2017-10-11 | ||||||||||||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||||||||||||
Full Title: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogeneic stem cel... | ||||||||||||||||||||||||||||
Medical condition: corticosteroid refractory chronic Graft vs Host Disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) AT (Completed) ES (Ongoing) BE (Completed) DK (Completed) NL (Completed) IT (Completed) FR (Completed) PT (Completed) HU (Completed) PL (Completed) BG (Completed) NO (Completed) GR (Completed) RO (Ongoing) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000238-23 | Sponsor Protocol Number: ExeBAT01 | Start Date*: 2016-08-09 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: The effect of Exenatide on brown adipose tissue activity and energy expenditure in healthy young men | ||
Medical condition: Healthy volunteers, intended indications: obesity and dyslipidemia | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000237-48 | Sponsor Protocol Number: MiraBAT01 | Start Date*: 2016-04-20 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: The effect of Mirabegron on brown adipose tissue in healthy young white Caucasian and South Asian men | ||
Medical condition: Obesity and dyslipidemia | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004267-20 | Sponsor Protocol Number: RIG-P000814 | Start Date*: 2016-09-01 | |||||||||||
Sponsor Name:Medical Center - University of Freiburg | |||||||||||||
Full Title: Multicenter, randomized Phase 2 Trial to determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) versus BAT in Steroid-refractory acute Graft-versus-Host Disease (aGvHD) | |||||||||||||
Medical condition: Steroid-refractory acute Graft-versus-Host Disease (GvHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002096-34 | Sponsor Protocol Number: AER-2012 | Start Date*: 2012-10-29 | |||||||||||
Sponsor Name:Crucell Holland B.V. | |||||||||||||
Full Title: Research towards presence of Antibodies against European Bat Lyssavirus (EBLV) after immunization with Rabipur® | |||||||||||||
Medical condition: healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003583-31 | Sponsor Protocol Number: CINC424B2401 | Start Date*: 2014-02-17 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: Randomized, open label, multicenter phase IIIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with polycythemia vera who are hydroxyurea resistant... | |||||||||||||
Medical condition: Polycythemia vera resistant or intolerant to hydroxyurea | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) HU (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001733-86 | Sponsor Protocol Number: 1710 | Start Date*: 2014-10-15 |
Sponsor Name:Maastricht University | ||
Full Title: The effect of L-arginine on brown adipose tissue metabolism in South Asian and white Caucasian subjects | ||
Medical condition: Obesity, glucose intolerance, endothelial dysfunction | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000731-31 | Sponsor Protocol Number: NL76746.068.21 | Start Date*: 2021-10-14 |
Sponsor Name:Maastricht University | ||
Full Title: Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in obese humans | ||
Medical condition: Type 2 diabetes mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001471-50 | Sponsor Protocol Number: 2015-IM-001 | Start Date*: 2016-03-31 |
Sponsor Name:CHU of Liege | ||
Full Title: Effect of preoperative infusion linisol on the postoperative quality sleep after open prostate surgery | ||
Medical condition: Post-operative sleep after open prostate surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001462-15 | Sponsor Protocol Number: MC-MSC.1/aGvHD | Start Date*: 2020-09-24 | |||||||||||
Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH | |||||||||||||
Full Title: A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refrac... | |||||||||||||
Medical condition: Steroid refractory Acute Graft versus host Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001935-21 | Sponsor Protocol Number: 8-55-52133-010 | Start Date*: 2011-08-30 | |||||||||||
Sponsor Name:IPSEN PHARMA SAS | |||||||||||||
Full Title: An interventional non-therapeutic study to assess ex vivo basophil activation in response to various preparations of taspoglutide and related items in blood samples from subjects who previously rec... | |||||||||||||
Medical condition: Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000557-27 | Sponsor Protocol Number: M20-178 | Start Date*: 2020-09-14 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis... | |||||||||||||
Medical condition: Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) SE (Prematurely Ended) PL (Prematurely Ended) GR (Completed) AT (Completed) DK (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) HR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002716-43 | Sponsor Protocol Number: APJ2015/DOTAMIR-CHEVALIER/VS | Start Date*: 2020-03-23 |
Sponsor Name:CHRU DE NANCY | ||
Full Title: Pilot Study evaluating somatostatin receptor's PET imaging to detect inflammatory phases of myocarditis | ||
Medical condition: infectious myocarditis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003532-39 | Sponsor Protocol Number: SitaBAT01 | Start Date*: 2014-11-24 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: The effect of sitagliptin on brown adipose tissue and whole-body metabolism in overweight pre-diabetic men | ||
Medical condition: Obesity, dyslipidemia and impaired glucose tolerance | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004703-23 | Sponsor Protocol Number: 1424R2131 | Start Date*: 2017-02-09 | ||||||||||||||||||||||||||
Sponsor Name:Shionogi Ltd. | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens | ||||||||||||||||||||||||||||
Medical condition: Hospital acquired pneumonia (HAP)/ventilator associated pneumonia (VAP)/healthcare-associated pneumonia (HCAP) or bloodstream infections/sepsis (BSI/sepsis) caused by carbapenem-resistant Gram-nega... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Completed) DE (Completed) GR (Completed) GB (Completed) HR (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000726-21 | Sponsor Protocol Number: D4280C00006 | Start Date*: 2012-09-11 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant G... | ||||||||||||||||||
Medical condition: cUTI, Complicated Urinary Tract Infection, cIAI, Complicated intra-abdominal infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) HU (Completed) IT (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-005007-13 | Sponsor Protocol Number: GS-US-352-1214 | Start Date*: 2014-10-21 | |||||||||||
Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibr... | |||||||||||||
Medical condition: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004427-37 | Sponsor Protocol Number: 5421234 | Start Date*: 2019-02-20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Odense Research Centre for Anaphylaxis (ORCA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Treatment with Omalizumab in food allergic children | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Food Allergy with Anaphylaxis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
